PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21393174-11	2011	Growth inhibition assays suggest that elvitegravir, raltegravir and vicriviroc are substrates of ABCB1.	Raltegravir Potassium	52-63	ATP binding cassette subfamily B member 1	Homo sapiens	97-102	
27097364-0	2016	Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants.	Raltegravir Potassium	40-51	ATP binding cassette subfamily B member 1	Homo sapiens	83-88	
27097364-1	2016	Raltegravir was recently identified to be a substrate of ATP-binding cassette transporter B1 (ABCB1) and G2 (ABCG2), which are efflux transporters and expressed in the intestines.	Raltegravir Potassium	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	57-92	
27097364-1	2016	Raltegravir was recently identified to be a substrate of ATP-binding cassette transporter B1 (ABCB1) and G2 (ABCG2), which are efflux transporters and expressed in the intestines.	Raltegravir Potassium	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	94-99	
27097364-2	2016	We analyzed the relations between plasma raltegravir concentrations and single nucleotide polymorphism of ABCB1 and ABCG2 genes.	Raltegravir Potassium	41-52	ATP binding cassette subfamily B member 1	Homo sapiens	106-111	
27097364-3	2016	The peak plasma concentration of raltegravir was significantly higher in the patients with ABCB1 4036 AG/GG and ABCG2 421 CA/AA than in other genotype holders (P = 0.0052), though no difference was identified in trough raltegravir concentrations, which may be explained by reduced expression of efflux transporters in intestine by these genetic variants.	Raltegravir Potassium	33-44	ATP binding cassette subfamily B member 1	Homo sapiens	91-96	
24872134-3	2014	In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens.	Raltegravir Potassium	120-131	ATP binding cassette subfamily B member 1	Homo sapiens	94-99	
24872134-3	2014	In the present study, we analyzed the relationship between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and raltegravir concentrations in 31 plasma and 14 CSF samples of HIV-infected patients treated with raltegravir-containing regimens.	Raltegravir Potassium	217-228	ATP binding cassette subfamily B member 1	Homo sapiens	94-99	
22450971-7	2012	Cellular accumulation studies were used to determine the effect of interplay between pH and ABCB1 transport on raltegravir accumulation.	Raltegravir Potassium	111-122	ATP binding cassette subfamily B member 1	Homo sapiens	92-97	
22450971-15	2012	Cellular accumulation of raltegravir was increased independently by inhibiting ABCB1 and by lowering extracellular pH from pH 8 to 5.	Raltegravir Potassium	25-36	ATP binding cassette subfamily B member 1	Homo sapiens	79-84	
23707228-0	2013	Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors.	Raltegravir Potassium	117-128	ATP binding cassette subfamily B member 1	Homo sapiens	17-31	
23707228-3	2013	Blood samples from 16 healthy volunteers were used to determine the expression of P-gp on total, T and T helper lymphocytes after exposure to darunavir, a second generation protease inhibitor, and raltegravir, the first approved integrase inhibitor.	Raltegravir Potassium	197-208	ATP binding cassette subfamily B member 1	Homo sapiens	82-86	
21078936-2	2011	Here we determined whether raltegravir was a substrate for ABCB1 or the influx transporters SLCO1A2, SLCO1B1, SLCO1B3, SLC22A1, SLC22A6, SLC10A1, SLC15A1, and SLC15A2.	Raltegravir Potassium	27-38	ATP binding cassette subfamily B member 1	Homo sapiens	59-64	
21078936-3	2011	Raltegravir transport by ABCB1 was studied with CEM, CEM(VBL100), and Caco-2 cells.	Raltegravir Potassium	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	25-30	
21078936-6	2011	Raltegravir was confirmed to be an ABCB1 substrate in CEM, CEM(VBL100), and Caco-2 cells.	Raltegravir Potassium	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	35-40